Limits...
IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, Guruge D, Ogg GS - Br. J. Cancer (2010)

Bottom Line: We observed that patients with malignancies had impaired VZV-specific T-cell responses, particularly in those with haematological malignancies and breast carcinoma.Immediate-early protein 63 (IE63)-specific T-cell responses were significantly impaired in those with subclinical VZV re-activation.Our results suggest that T-cell responses to IE63 are important in controlling VZV replication.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.

ABSTRACT

Background: Reactivation of the varicella zoster virus (VZV) is more common in patients with malignancies; however, the molecular and cellular mechanisms underlying this susceptibility are unclear.

Methods: Using ex vivo interferon-gamma ELISpot assays, we set out to analyse VZV-specific immune responses in a large cohort of patients with malignancies.

Results: We observed that patients with malignancies had impaired VZV-specific T-cell responses, particularly in those with haematological malignancies and breast carcinoma. Immediate-early protein 63 (IE63)-specific T-cell responses were significantly impaired in those with subclinical VZV re-activation.

Conclusions: Our results suggest that T-cell responses to IE63 are important in controlling VZV replication.

Show MeSH

Related in: MedlinePlus

Ex vivo IFNγ ELISpot responses to VZV live attenuated vaccine, overlapping gE 20-mer peptide pool and overlapping IE63 20-mer peptide pools in patients with malignancies and healthy seropositive volunteers with no evidence of VZV reactivation.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2837573&req=5

fig1: Ex vivo IFNγ ELISpot responses to VZV live attenuated vaccine, overlapping gE 20-mer peptide pool and overlapping IE63 20-mer peptide pools in patients with malignancies and healthy seropositive volunteers with no evidence of VZV reactivation.

Mentions: We observed that overall VZV-specific T-cell responses were significantly diminished (P<0.0001) in patients with malignancies (mean 170.9, s.d.±244.3) when compared with healthy VZV seropositive individuals (mean 511.3, s.d.±372.3; Figure 1). Patients with haematological malignancies and breast cancer had the lowest VZV-specific T-cell responses. Those with haematological malignancies had significantly lower overall T-cell responses to VZV (as measured by responses to the VZV live attenuated vaccine) than those with solid malignancies (Table 1; P<0.05). However, there was no difference between the two groups for gE or IE63 overlapping 20-mer peptides (Figure 2). Among those with solid malignancies, patients with breast carcinoma had significantly lower VZV-specific T-cell responses (P<0.0001). The overall VZV-specific T-cell responses in individuals with different malignancies are shown in Table 1. Patients with haematological malignancies had significantly higher (P<0.05) total white cell count (mean 11 746, s.d.±9079) and significantly higher (P<0.005) lymphocyte count (mean 3986, s.d.±3986) than patients with solid malignancies. However, we found no correlation with the T-cell response with either total white cell or lymphocyte counts. We also observed no correlation between VZV-specific T-cell responses and age of the individual or time since occurrence of primary infection.


IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, Guruge D, Ogg GS - Br. J. Cancer (2010)

Ex vivo IFNγ ELISpot responses to VZV live attenuated vaccine, overlapping gE 20-mer peptide pool and overlapping IE63 20-mer peptide pools in patients with malignancies and healthy seropositive volunteers with no evidence of VZV reactivation.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2837573&req=5

fig1: Ex vivo IFNγ ELISpot responses to VZV live attenuated vaccine, overlapping gE 20-mer peptide pool and overlapping IE63 20-mer peptide pools in patients with malignancies and healthy seropositive volunteers with no evidence of VZV reactivation.
Mentions: We observed that overall VZV-specific T-cell responses were significantly diminished (P<0.0001) in patients with malignancies (mean 170.9, s.d.±244.3) when compared with healthy VZV seropositive individuals (mean 511.3, s.d.±372.3; Figure 1). Patients with haematological malignancies and breast cancer had the lowest VZV-specific T-cell responses. Those with haematological malignancies had significantly lower overall T-cell responses to VZV (as measured by responses to the VZV live attenuated vaccine) than those with solid malignancies (Table 1; P<0.05). However, there was no difference between the two groups for gE or IE63 overlapping 20-mer peptides (Figure 2). Among those with solid malignancies, patients with breast carcinoma had significantly lower VZV-specific T-cell responses (P<0.0001). The overall VZV-specific T-cell responses in individuals with different malignancies are shown in Table 1. Patients with haematological malignancies had significantly higher (P<0.05) total white cell count (mean 11 746, s.d.±9079) and significantly higher (P<0.005) lymphocyte count (mean 3986, s.d.±3986) than patients with solid malignancies. However, we found no correlation with the T-cell response with either total white cell or lymphocyte counts. We also observed no correlation between VZV-specific T-cell responses and age of the individual or time since occurrence of primary infection.

Bottom Line: We observed that patients with malignancies had impaired VZV-specific T-cell responses, particularly in those with haematological malignancies and breast carcinoma.Immediate-early protein 63 (IE63)-specific T-cell responses were significantly impaired in those with subclinical VZV re-activation.Our results suggest that T-cell responses to IE63 are important in controlling VZV replication.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.

ABSTRACT

Background: Reactivation of the varicella zoster virus (VZV) is more common in patients with malignancies; however, the molecular and cellular mechanisms underlying this susceptibility are unclear.

Methods: Using ex vivo interferon-gamma ELISpot assays, we set out to analyse VZV-specific immune responses in a large cohort of patients with malignancies.

Results: We observed that patients with malignancies had impaired VZV-specific T-cell responses, particularly in those with haematological malignancies and breast carcinoma. Immediate-early protein 63 (IE63)-specific T-cell responses were significantly impaired in those with subclinical VZV re-activation.

Conclusions: Our results suggest that T-cell responses to IE63 are important in controlling VZV replication.

Show MeSH
Related in: MedlinePlus